HK1204552A1 - Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1- [(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-((1r,2s)-1- [(cyclopropylsulfonyl)carbamoyl]-2- ethenylcyclopropylcarbamoyl)pyrrolidin-1-yl]carbonyl-2,2- dimethylpropyl]carbamate [(1s)-1-[(2s4r)-4-(7--4--1-)-2-((1r2s)-1- [()]-2-)-1-]- 22-] 11- - Google Patents

Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1- [(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-((1r,2s)-1- [(cyclopropylsulfonyl)carbamoyl]-2- ethenylcyclopropylcarbamoyl)pyrrolidin-1-yl]carbonyl-2,2- dimethylpropyl]carbamate [(1s)-1-[(2s4r)-4-(7--4--1-)-2-((1r2s)-1- [()]-2-)-1-]- 22-] 11-

Info

Publication number
HK1204552A1
HK1204552A1 HK15105032.2A HK15105032A HK1204552A1 HK 1204552 A1 HK1204552 A1 HK 1204552A1 HK 15105032 A HK15105032 A HK 15105032A HK 1204552 A1 HK1204552 A1 HK 1204552A1
Authority
HK
Hong Kong
Prior art keywords
ethenylcyclopropylcarbamoyl
cyclopropylsulfonyl
dimethylpropyl
dimethylethyl
yloxy
Prior art date
Application number
HK15105032.2A
Other languages
English (en)
Chinese (zh)
Inventor
Robert Kevin Perrone
Original Assignee
Bristol Myers Squibb Holdings Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48428670&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1204552(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Holdings Ireland filed Critical Bristol Myers Squibb Holdings Ireland
Publication of HK1204552A1 publication Critical patent/HK1204552A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15105032.2A 2012-05-07 2015-05-27 Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1- [(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-((1r,2s)-1- [(cyclopropylsulfonyl)carbamoyl]-2- ethenylcyclopropylcarbamoyl)pyrrolidin-1-yl]carbonyl-2,2- dimethylpropyl]carbamate [(1s)-1-[(2s4r)-4-(7--4--1-)-2-((1r2s)-1- [()]-2-)-1-]- 22-] 11- HK1204552A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261643454P 2012-05-07 2012-05-07
PCT/US2013/038770 WO2013169520A1 (en) 2012-05-07 2013-04-30 Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate

Publications (1)

Publication Number Publication Date
HK1204552A1 true HK1204552A1 (en) 2015-11-27

Family

ID=48428670

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15105032.2A HK1204552A1 (en) 2012-05-07 2015-05-27 Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1- [(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-((1r,2s)-1- [(cyclopropylsulfonyl)carbamoyl]-2- ethenylcyclopropylcarbamoyl)pyrrolidin-1-yl]carbonyl-2,2- dimethylpropyl]carbamate [(1s)-1-[(2s4r)-4-(7--4--1-)-2-((1r2s)-1- [()]-2-)-1-]- 22-] 11-

Country Status (33)

Country Link
US (1) US20130302414A1 (es)
EP (1) EP2846780B1 (es)
JP (1) JP6276756B2 (es)
KR (1) KR20150004921A (es)
CN (1) CN104363899A (es)
AR (1) AR090954A1 (es)
AU (1) AU2013260005B2 (es)
BR (1) BR112014027676A2 (es)
CA (1) CA2872765A1 (es)
CL (1) CL2014003012A1 (es)
CO (1) CO7141457A2 (es)
CY (1) CY1120756T1 (es)
DK (1) DK2846780T3 (es)
EA (1) EA028749B1 (es)
ES (1) ES2688817T3 (es)
HK (1) HK1204552A1 (es)
HR (1) HRP20181583T1 (es)
IL (1) IL235466B (es)
LT (1) LT2846780T (es)
MX (1) MX358545B (es)
MY (1) MY171378A (es)
NZ (1) NZ630248A (es)
PE (1) PE20142439A1 (es)
PH (1) PH12014502405A1 (es)
PL (1) PL2846780T3 (es)
PT (1) PT2846780T (es)
RS (1) RS57881B1 (es)
SG (1) SG11201406964QA (es)
SI (1) SI2846780T1 (es)
TW (1) TWI577392B (es)
UY (1) UY34785A (es)
WO (1) WO2013169520A1 (es)
ZA (1) ZA201408967B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150119317A1 (en) * 2012-05-07 2015-04-30 Bristol-Myers Squibb Company Oral solid dosage formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
EA025560B1 (ru) 2012-10-19 2017-01-30 Бристол-Майерс Сквибб Компани Ингибиторы вируса гепатита с
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2964664B1 (en) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2019130341A1 (en) * 2017-12-26 2019-07-04 Hetero Labs Limited Capsule compositions comprising lopinavir and ritonavir

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
KR100847679B1 (ko) * 2000-10-31 2008-07-23 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 피라논 프로테아제 억제제의 경구 투여 자가-유화 제형
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
EP2346329B1 (en) * 2008-10-09 2013-08-21 Anadys Pharmaceuticals, Inc. A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound

Also Published As

Publication number Publication date
PH12014502405A1 (en) 2015-01-12
KR20150004921A (ko) 2015-01-13
MY171378A (en) 2019-10-10
JP6276756B2 (ja) 2018-02-07
BR112014027676A2 (pt) 2017-06-27
CL2014003012A1 (es) 2015-07-10
MX2014013220A (es) 2015-05-11
MX358545B (es) 2018-08-24
PT2846780T (pt) 2018-10-26
LT2846780T (lt) 2018-11-12
EP2846780A1 (en) 2015-03-18
JP2015516418A (ja) 2015-06-11
US20130302414A1 (en) 2013-11-14
IL235466B (en) 2019-03-31
EA028749B1 (ru) 2017-12-29
SI2846780T1 (sl) 2018-09-28
CA2872765A1 (en) 2013-11-14
EA201492039A1 (ru) 2015-02-27
RS57881B1 (sr) 2019-01-31
PE20142439A1 (es) 2015-01-28
WO2013169520A1 (en) 2013-11-14
ES2688817T3 (es) 2018-11-07
AU2013260005A1 (en) 2015-01-15
NZ630248A (en) 2016-11-25
UY34785A (es) 2013-11-29
DK2846780T3 (en) 2018-09-17
CN104363899A (zh) 2015-02-18
PL2846780T3 (pl) 2018-11-30
EP2846780B1 (en) 2018-07-18
CO7141457A2 (es) 2014-12-12
TWI577392B (zh) 2017-04-11
ZA201408967B (en) 2016-10-26
HRP20181583T1 (hr) 2018-11-30
TW201350145A (zh) 2013-12-16
AU2013260005B2 (en) 2017-07-13
CY1120756T1 (el) 2019-12-11
AR090954A1 (es) 2014-12-17
SG11201406964QA (en) 2014-11-27

Similar Documents

Publication Publication Date Title
HK1204552A1 (en) Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1- [(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-((1r,2s)-1- [(cyclopropylsulfonyl)carbamoyl]-2- ethenylcyclopropylcarbamoyl)pyrrolidin-1-yl]carbonyl-2,2- dimethylpropyl]carbamate [(1s)-1-[(2s4r)-4-(7--4--1-)-2-((1r2s)-1- [()]-2-)-1-]- 22-] 11-
EP2917180A4 (en) GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE SUBSTANCE
WO2013152059A8 (en) Multicolored ph-activatable fluorescence nanoplatform
MX359288B (es) Forma iv del clorhidrato de ivabradina.
WO2013171764A3 (en) Ophthalmic formulations
HUS2300030I1 (hu) N-(2-metoxibenzoil)-4-[(metilaminokarbonil)amino]benzolszulfonamid polimorf formája
WO2013181339A3 (en) Cyclosporin a analogs
HK1204937A1 (en) Pharmaceutical composition comprising (1r,4r)-6-fluoro-n,n-dimethyl- 4-phenyl-4,9-dihydro-3h-spiro[cyclohexane-1,1-pyrano [3,4,b]indol]-4-amine and an anticonvulsant (1r4r)-6--nn--4--49--3h-[- 11-[34b]]-4-
EP2871187A4 (en) NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT
EP2654725A4 (en) MICROPARTICLE WITH PHYSIOLOGICALLY ACTIVE PEPTIDE, PROCESS FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION THEREWITH
EP2886112A4 (en) COMPOSITION CONTAINING AS ACTIVE INGREDIENT OF S-ALLYL-L-CYSTEINE FOR PREVENTING OR TREATING OCULAR DISEASES, AND PHARMACEUTICAL FORMULATION COMPRISING THE SAME
HK1204943A1 (en) Pharmaceutical composition comprising (1r,4r)-6-fluoro-n,n-dimethyl- 4-phenyl-4,9-dihydro-3h-spiro[cyclohexane-1,1-pyrano [3,4,b]indol]-4-amine and a gabapentinoid (1r4r)-6--nn--4--49--3h-[-1 1-[34b]]-4-
HK1204938A1 (en) Pharmaceutical composition comprising (1r,4r)-6-fluoro-n,n-dimethyl- 4-phenyl-4,9-dihydro-3h-spiro[cyclohexane-1,1-pyrano [3,4,b]indol]-4-amine and a nsar (1r4r)-6--nn--4--49--3h-[- 11-[34b]]-4- nsar
EP2882435B8 (en) Pharmaceutical formulations containing 3-(4-cinnamyl-L-piperazinyl) amino derivatives of 3-formylrifamycin S
WO2014013511A3 (en) Rufinamide solid dispersion
PL2678006T3 (pl) Pakowanie stałych preparatów farmaceutycznych zawierających substancję aktywną triazotan glicerolu
HK1204944A1 (en) Pharmaceutical composition comprising (1r,4r)-6-fluoro-n,n-dimethyl- 4-phenyl-4,9-dihydro-3h-spiro[cyclohexane-1,1-pyrano [3,4,b]indol]-4-amine and antidepressants (1r4r)-6--nn--4--49--3h-[- 11-[34b]]-4-
WO2013153161A3 (en) Polymorph of rilpivirine hydrochloride
CA2865484A1 (en) Stabilized controlled-release pharmaceutical composition comprising gliclazide
HK1204940A1 (en) Pharmaceutical composition comprising (1r,4r)-6-fluoro-n,n-dimethyl- 4-phenyl-4,9-dihydro-3h-spiro[cyclohexane-1,1- pyrano[3,4,b]indol]-4-amine and paracetamol or propacetamol (1r4r)-6--nn--4--49--3h-[- 11-[34b]]-4-
TH1401006625A (th) สูตรผสมแคปซูลที่ละลายได้ของ 1,1-ไดเมธิลเอธิล[(1s)-1{[2s,4r)-4-(7-คลอโร-4เมธอกซีไอโซควิโนลิน-1-อิลออกซี)-2-({1r,2s)-1-[(ไซโคลโพรพิลซัลโฟนิล) คาร์บาโมอิล]-2-เอธีนิลไซโคลโพรพิล}คาร์บาโมอิล)ไพร์โรลิดิน-1-อิล]คาร์บอนิล}-2,2-ไดเมธิลโพรพิล]คาร์บาเมต
HK1204939A1 (en) Pharmaceutical composition comprising (1r,4r)-6-fluoro-n,n-dimethyl- 4-phenyl-4,9-dihydro-3h-spiro[cyclohexane-1,1-pyrano [3,4,b]indol]-4-amine and an oxicam (1r4r)-6--nn--4--49--3h-[- 11-[34b]]-4-
HK1204941A1 (en) Pharmaceutical composition comprising (1r,4r)-6-fluoro-n,n-dimethyl- 4-phenyl-4,9-dihydro-3h-spiro [cyclohexane-1,1-pyrano- [3,4,b]indol]-4-amine and a salicylic acid component (1r4r)-6--nn--4--49--3h-[- 11-[34b]]-4-
WO2013127539A3 (de) Pharmazeutische formulierung enthaltend flupirtin
GB201202149D0 (en) Anti-aging mixtures, pure substance and drug called "laundrin"

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230427